Negative briefing docs drop Chelsea; could be tough sell for Northera
By Jennifer Boggs
Friday, January 10, 2014
Executives of Chelsea Therapeutics International Ltd. have their work cut out for them Tuesday, as briefing documents released ahead of the Cardiovascular and Renal Drugs Advisory Committee questioned whether data are sufficient to prove the efficacy of previously rejected neurogenic orthostatic hypotension (NOH) drug Northera (droxidopa).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.